About Hemogenyx Pharmaceuticals plc Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and ...

The Filipino-born artist takes a journey through primordial mud, chimeric worlds, and suppressed psychic demons to honor trans people as channels of divinity.

The field of engineered cell therapies is rapidly advancing, offering promising new treatments for autoimmune conditions and cancer. Recent applications, particularly the use of chimeric antigen ...

Carisma Therapeutics (CARM) announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte, or CAR-M, therapy for hepatocellular carcinoma, or HCC, ...

UC San Francisco treated its first brain cancer patient with an experimental new CAR-T therapy discovered and manufactured at ...

These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target ...

Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, ...

Researchers find that a gene linked to Alzheimer's triggers inflammation in healthy brain immune cells, offering new insights ...

Carisma Therapeutics (CARM) announced the upcoming presentation of new pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor ...

BGB-16673, which induces BTK degradation, is the first and most advanced asset from BeiGene’s chimeric degradation activation compound (CDAC) platform. Oral presentation of the ...

FREDERICK, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that ...